GLP-1 moiety from Dulaglitude,HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG
>96%
- Product Code: 105919
| Molecular Weight: | 3314.62 g./mol | Molecular Formula: | C₁₄₉H₂₂₁N₃₇O₄₉ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C |
Product Description:
The GLP-1 moiety derived from Dulaglutide is primarily utilized in the treatment of type 2 diabetes mellitus. It functions as an incretin mimetic, enhancing glucose-dependent insulin secretion from pancreatic beta cells. This leads to improved blood sugar control in patients. Additionally, it suppresses glucagon secretion, which reduces hepatic glucose production. The moiety also slows gastric emptying, contributing to a feeling of fullness and aiding in weight management. Its long-acting nature, due to the fusion with an Fc fragment, allows for once-weekly administration, improving patient compliance. Furthermore, it has shown potential in reducing cardiovascular risks, making it a valuable therapeutic option for diabetic patients with associated cardiovascular conditions.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.001 | 10-20 days | ฿25,200.00 |
+
-
|
GLP-1 moiety from Dulaglitude,HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG
The GLP-1 moiety derived from Dulaglutide is primarily utilized in the treatment of type 2 diabetes mellitus. It functions as an incretin mimetic, enhancing glucose-dependent insulin secretion from pancreatic beta cells. This leads to improved blood sugar control in patients. Additionally, it suppresses glucagon secretion, which reduces hepatic glucose production. The moiety also slows gastric emptying, contributing to a feeling of fullness and aiding in weight management. Its long-acting nature, due to the fusion with an Fc fragment, allows for once-weekly administration, improving patient compliance. Furthermore, it has shown potential in reducing cardiovascular risks, making it a valuable therapeutic option for diabetic patients with associated cardiovascular conditions.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :